je.st
news
Gilead Announces Interim Phase 2 Results for GS-9973 in Previously...
2013-12-08 05:39:25| Biotech - Topix.net
Gilead Sciences, Inc. today announced interim results from a single-arm, open-label Phase 2 study evaluating GS-9973, an investigational oral inhibitor of spleen tyrosine kinase , for the treatment of patients with relapsed or refractory hematologic malignancies.
Tags: in
results
previously
phase
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||